Saudi Arabia Dengue Testing Market (2026 - 2033) Size, Share & Trends Analysis Report By Test Type (ELISA Based Tests, Molecular Diagnostic Tests, Rapid Diagnostic Tests (RDTs)), By Product (Consumables, Instruments), By End Use (Hospitals), And Segment Forecasts

Saudi Arabia Dengue Testing Market Size & Trends

Rising mosquito-borne disease surveillance activities and growing awareness of early diagnosis are increasing demand for accurate dengue testing methods, including RT-PCR, ELISA, NS1 antigen testing, and rapid diagnostic tests (RDTs).

Market Dynamics

Market Concentration & Characteristics

The Saudi Arabia dengue testing market demonstrates a moderate to high degree of innovation, driven by the increasing adoption of advanced diagnostic technologies such as RT-PCR, ELISA, multiplex molecular assays, and automated immunoassay systems. Healthcare facilities are also integrating digital laboratory solutions and high-throughput testing platforms to improve diagnostic accuracy, efficiency, and turnaround times. A November 2025 study published in International Health evaluated the combined use of NS1 antigen testing and IgM ELISA against RT-PCR across six regions in Saudi Arabia. The study found that combining NS1 and IgM tests increased diagnostic sensitivity to 92.4%, highlighting the growing adoption of multi-platform diagnostic approaches to improve dengue detection and surveillance in the country.

The Saudi Arabia dengue testing market is witnessing moderate merger, acquisition, and strategic partnership activity as diagnostic companies expand their molecular testing capabilities, local manufacturing presence, and infectious disease portfolios. Companies are entering joint ventures and regional collaborations to strengthen access to advanced PCR and rapid diagnostic technologies. These partnerships support the localization of diagnostic production, improve testing accessibility, and enhance infectious disease surveillance capabilities across the Kingdom.

Regulatory frameworks play a significant role in shaping the Saudi Arabia dengue testing market by ensuring the safety, quality, and accuracy of diagnostic tests, including RT-PCR, ELISA, and rapid antigen assays. The Saudi Food and Drug Authority (SFDA) has established strict approval and quality requirements for in-vitro diagnostic devices, thereby increasing compliance costs and extending product registration timelines for manufacturers. However, these regulations support market growth by promoting the adoption of reliable and clinically validated dengue diagnostic solutions across hospitals, laboratories, and public health institutions. The implementation of stringent regulatory standards and post-market surveillance further improves confidence in diagnostic testing and strengthens infectious disease monitoring in the country.

The market is being driven by the rising incidence of dengue infections, increasing government focus on infectious disease surveillance, and ongoing improvements in healthcare infrastructure across the country. Diagnostic companies are expanding their presence through partnerships with hospitals, laboratories, and public health agencies to strengthen dengue detection capabilities. Expanding healthcare services in high-risk regions such as Jeddah, Makkah, and Jazan, along with increased awareness of early disease diagnosis and outbreak management, is further driving the adoption of dengue testing solutions across Saudi Arabia.

Test Type Insights

The ELISA based tests segment dominated the Saudi Arabia dengue testing market, accounting for the largest revenue share of 31.73% in 2025. The adoption of ELISA-based tests in dengue testing in Saudi Arabia is increasing due to their high sensitivity, cost-effectiveness, and suitability for large-scale screening programs. ELISA tests are widely used to detect dengue NS1 antigens and IgM and IgG antibodies, enabling healthcare providers to identify both early-stage and past infections with high accuracy. These tests are particularly valuable in hospital laboratories and public health surveillance programs because they can process a large number of samples simultaneously, which is essential during seasonal outbreaks and mass screening initiatives. The increasing dengue burden in regions such as Jeddah and Makkah has also prompted healthcare authorities to strengthen laboratory diagnostic capabilities, thereby increasing demand for ELISA-based testing platforms. In addition, Saudi Arabia’s growing investments in infectious disease monitoring, vector-borne disease control programs, and improved laboratory infrastructure are supporting the wider adoption of ELISA diagnostics.

The molecular diagnostic kits segment is anticipated to grow at the fastest CAGR of 5.99% over the forecast period. Molecular diagnostic tests are being adopted in Saudi Arabia for their ability to provide accurate, early detection of dengue virus infections. Techniques such as RT-PCR are widely used in hospitals and reference laboratories to detect dengue virus RNA at the early stage of infection, enabling healthcare professionals to initiate timely patient management and reduce the risk of severe complications. According to an article published in Transactions of the Royal Society of Tropical Medicine and Hygiene in April 2026, researchers in Saudi Arabia reported that dengue diagnosis across seven regions was primarily conducted using RT-PCR molecular testing, with more than 2,850 suspected patient samples analyzed. The study identified 1,447 PCR-confirmed dengue cases. Such cases highlight the increasing reliance on molecular diagnostic kits for accurate outbreak surveillance and infection monitoring

Product Insights

The consumables segment held the largest share of the Saudi Arabia dengue testing market, accounting for 77.04% in 2025. The segment is driven by the increasing demand for dengue diagnostic procedures across hospitals, laboratories, and healthcare centers. Consumables include reagents, assay kits, PCR cartridges, sample collection swabs, buffers, and rapid diagnostic test kits required for every testing process. Since these products are disposable and require continuous replenishment, their demand rises directly with increases in dengue testing volumes. Rising awareness regarding early disease diagnosis and infection control has encouraged healthcare providers to conduct more screening and confirmatory tests. A December 2025 study conducted across six regions in Saudi Arabia used large volumes of NS1 antigen tests, IgM/IgG ELISA kits, and RT-PCR assays to evaluate more than 2,850 patient samples for dengue diagnosis. This highlights the growing routine consumption of reagents, assay kits, and PCR consumables in hospitals and regional laboratories.

The others segment is expected to grow significantly over the forecast period. The segment is driven by increasing demand for diagnostic materials used during dengue detection procedures. As hospitals and laboratories conduct more dengue tests, demand for reagents, assay kits, sample collection products, quality control materials, and laboratory accessories is also rising. These products are essential for ensuring accurate and reliable test results in RT-PCR, ELISA, and rapid diagnostic testing methods. In addition, the growing focus on early disease detection and infection surveillance in Saudi Arabia is encouraging healthcare facilities to improve their laboratory capabilities. This has increased the use of specialized diagnostic support products and testing components. The expansion of automated laboratory systems and molecular diagnostic technologies is further driving demand in this segment. 

End Use Insights

The hospitals segment dominated the Saudi Arabia dengue testing market, accounting for the largest revenue share of 42.68% in 2025, driven by the rising number of mosquito-borne infections and the increasing need for early and accurate diagnosis. Hospitals remain the primary centers for dengue testing because they are equipped with advanced laboratory infrastructure, molecular diagnostic technologies, and skilled healthcare professionals. Patients with moderate to severe dengue symptoms are commonly treated in hospitals, increasing demand for rapid, reliable diagnostic methods such as RT-PCR, ELISA, and NS1 antigen tests. Hospitals also play a major role in disease surveillance, outbreak monitoring, and infection control, particularly in high-risk regions including Makkah, Jeddah, and Jazan. The growth of hospital-based testing is further supported by Saudi Arabia’s increasing healthcare investments and stronger infectious disease surveillance programs. Hospitals are adopting combined diagnostic approaches, such as NS1 antigen and IgM ELISA testing, to improve diagnostic accuracy and reduce testing time.

The research institutes segment is expected to grow at the fastest CAGR over the forecast period, fueled by the country’s increasing focus on strengthening infectious disease surveillance and advancing diagnostic research. Research institutes and academic centers play an important role in studying the spread patterns of mosquito-borne diseases, particularly in regions where dengue cases are more frequently reported. Their work helps in understanding seasonal trends, transmission behavior, and risk factors associated with outbreaks, which supports better preparedness and response strategies. In addition, Saudi Arabia is placing strong emphasis on developing advanced diagnostic technologies and improving early detection of infectious diseases such as dengue and Zika. Research institutes contribute significantly to this goal by conducting clinical studies, validating molecular diagnostic methods, and supporting the development of innovative tools for disease detection and vector monitoring. These activities are essential for improving the accuracy and speed of testing, which is critical for effective disease control

Key Saudi Arabia Dengue Testing Company Insights

Key players operating in the market are undertaking various initiatives to strengthen their market presence and increase the reach of their technology and services. Strategies such as expansion activities and partnerships are playing a key role in propelling the market growth.

Key Saudi Arabia Dengue Testing Companies:

• Abbott

• F. Hoffmann-La Roche Ltd

• Thermo Fisher Scientific, Inc.

• Bio-Rad Laboratories, Inc.

• SD Biosensor, Inc.

• QuidelOrtho Corporation

• InBios International, Inc.

• CTK Biotech, Inc.

• GENBODY INC. 

Competitive Benchmarking 

Recent Developments

• In April 2026, Co-Diagnostics announced a joint venture with Arabian Eagle Manufacturing to establish CoMira Diagnostics in Saudi Arabia for the development, manufacturing, and commercialization of molecular diagnostic technologies.

• In December 2025, a study published in Sensors reviewed next-generation dengue diagnostic technologies, including CRISPR-based assays, biosensors, AI-enabled diagnostics, and microfluidic platforms, amid rising dengue incidence in Saudi Arabia, highlighting the growing focus on advanced testing innovation.

Saudi Arabia Dengue Testing Market Report Scope

Saudi Arabia Dengue Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Saudi Arabia dengue testing market report based on test type, product, and end use:

• Test Type (Revenue, USD Thousands, 2021 - 2033)

  • ELISA-Based Tests

  • Molecular Diagnostic Kits

  • Rapid Diagnostic Tests (RDTs)

  • Lateral Flow Assays (Antigen-Based)

• Product Outlook (Revenue, USD Thousands, 2021 - 2033)

  • Consumables

  • Instruments

  • Others

• End Use Outlook (Revenue, USD Thousands, 2021 - 2033)

  • Hospitals

  • Diagnostic Laboratories

  • Government & Public Health Laboratories

  • Research Institutes

Delivered Customizations

This report has been delivered with the following In-depth customizations